Skip to main content
D

DNA Group (T.R.) Ltd. — Investor Relations & Filings

Ticker · DNA ISIN · IL0011038523 TA Manufacturing
Open in API
Filings indexed 22 across all filing types
Latest filing 2020-09-01 Environmental & Social …
Country IL Israel
Listing TA DNA

About DNA Group (T.R.) Ltd.

http://www.dnas.co.il

DNA Group (T.R.) Ltd., formerly DNA Biomedical Solutions Ltd., is a company engaged in the biotechnology sector. Through its subsidiaries, it develops, manufactures, and markets patented ultrasound systems. The company also invests in biomedical companies and real estate.

Recent filings

Filing Released Lang Actions
Analysis update following financial report:price target is unchanged NIS 2.62
Environmental & Social Information Classification · 1% confidence The document contains structured data, likely related to financial metrics or indices, given the presence of dates (e.g., 01/09/2020, 25/04/2020), numerical values (e.g., 0.83, 8.13, 2.62), and references to a specific entity ("FROST & SULLIVAN RESEARCH & CONSULTING LTD") and a file name ("Frost_and_Sullivan_DNA_EngQ220_isa.pdf"). The structure, which lists historical data points with associated dates and values, strongly suggests a data supplement rather than a narrative report (like 10-K, ER, or IR). Since the data is presented in a tabular/structured format, and the context implies supplementary financial information, the most appropriate classification is Financial Supplement Data (XLSX), even though the provided text is not strictly an XLSX file, but rather the content that would typically accompany or be derived from such a supplement, especially when dealing with historical data points that are often provided in spreadsheet format for analysis. The document length is moderate (5426 chars), but the content is highly structured data points, not a full narrative report or a simple announcement.
2020-09-01 Russian
update analsis (FORST),price target is unchanged
Earnings Release Classification · 1% confidence The document is titled 'Q2 20 Update August 24, 2020' and contains detailed analysis, stock target prices, financial updates (mentioning the second quarter report), clinical trial progress, and future catalysts for Entera Bio. It is explicitly branded as 'Frost & Sullivan Research & Consulting Ltd.' and includes a section on 'Independent Equity Research'. This structure—a detailed analysis report covering performance, outlook, and specific catalysts, often published by a third-party research firm—strongly indicates it is an Investor Presentation (IP) or a detailed research report, rather than a formal regulatory filing like a 10-K or an ER press release. Since it is a comprehensive analysis document intended for investors, 'Investor Presentation' (IP) is the most fitting category, as it often encompasses the content of initiation or update reports. Q2 2020
2020-08-24 English
update analsis (FORST),price target is unchanged
Investor Presentation Classification · 1% confidence The document contains structured data, company identifiers (like stock exchange codes and company numbers), dates, and references to external documents (e.g., 'Frost_and_Sullivan_DNA_EngQ220_isa.pdf'). The content appears to be a regulatory filing or a structured data submission, possibly related to a specific reporting requirement or a data feed, given the tabular format and the presence of dates and numerical values associated with historical entries. The presence of 'FROST & SULLIVAN RESEARCH & CONSULTING LTD' suggests external analysis or reporting. Since the text is highly structured, contains historical data points (ratios/values over time), and lacks the narrative structure of an Earnings Release (ER) or Interim Report (IR), it is most likely supplementary data or a specific regulatory filing that doesn't fit the primary categories. Given the context of financial data presentation over time, and lacking clear indicators for AGM, 10-K, or ER, the most appropriate general category for structured, non-narrative financial data that might accompany a main report, or be a specific data submission, is often 'Regulatory Filings' (RNS) if it's a general announcement, or potentially 'Financial Supplement Data' (XLSX) if it represents raw data, although the format here is text-based. However, the structure strongly suggests a standardized report or data submission rather than a simple announcement of a report. Given the mix of data points and the reference to an attached PDF, it resembles a data supplement or a specific regulatory filing. Since it is not a clear 10-K, IR, or ER, and it's not a simple announcement (it contains substantial data), I will lean towards a specific data/supplement type if available, or RNS. The data points look like historical metrics or ratios. Without a clear title like 'Financial Supplement', 'Regulatory Filings' (RNS) serves as the best fit for a structured, non-standard report type.
2020-08-24 Russian
Quarterly analysis update report
Investor Presentation Classification · 1% confidence The document is an 'Independent Equity Research' report produced by Frost & Sullivan regarding DNA Biomedical Solutions Ltd. and its subsidiary Entera Bio. It provides an analysis of the company's business model, clinical trial progress, market potential, and investment catalysts. It is not a primary financial filing (like a 10-K or IR) nor a simple announcement, but rather an external analyst report. Given the provided categories, 'Investor Presentation' (IP) is the closest fit for detailed research and strategic analysis documents intended for investor consumption, although it functions as an analyst research report. Q1 2020
2020-06-10 English
Quarterly analysis update report
Investor Presentation Classification · 1% confidence The document text is heavily garbled (appears to be Hebrew text encoded incorrectly or displayed as mojibake), but several key structural elements and keywords suggest its nature. It contains references to 'FROST & SULLIVAN RESEARCH & CONSULTING LTD', dates (e.g., 10/06/2020), and a final line referencing a PDF file: '���� ���� ����� 1, 2020* ��"� ����� �������: *Frost_and_Sullivan_DNA_EngQ120_isa.pdf*'. The presence of a specific, named report file attached or referenced, combined with the structure that seems to list historical data points (ratios/metrics with dates), strongly suggests this is an announcement or cover page for a research report or factsheet, rather than the full regulatory filing itself (like a 10-K or IR). Given the reference to 'Frost & Sullivan' and the structure, it is likely an Investor Presentation (IP) or a Fund Information/Factsheet (FS). Since it references a specific research document ('Frost_and_Sullivan_DNA_EngQ120_isa.pdf') and seems to be a summary/cover page, 'Investor Presentation' (IP) is a strong candidate for detailed analysis material, or 'FS' for a factsheet. However, the structure listing historical metrics over time (09/10/2017 through 10/06/2020) is very common in Investor Presentations (IP) used to show trends. I will classify it as an Investor Presentation (IP) as it appears to be a summary document leading to a detailed report.
2020-06-10 Russian
Analysis update following financial report:target price is set at NIS 2.62
Investor Presentation Classification · 1% confidence The document is an independent equity research report produced by Frost & Sullivan regarding DNA Biomedical Solutions Ltd. It provides a company overview, investment analysis, market context, and a summary of financial highlights. While it contains some financial data in the appendix, it is not a primary financial statement (10-K or IR) but rather an analyst research report. Since 'Equity Research' is not a specific category in the provided list, and it functions as a detailed presentation of investment strategy and company outlook, it aligns best with the 'Investor Presentation' (IP) category, which covers detailed documents focusing on strategy and market position. H1 2019
2020-04-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.